Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion
U.S: Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidrafor an upfront payment of $3.4 billion to expand its portfolio of eye care medicines.
Read Also: Novartis division strikes deal with Eir Genix to market biosimilar of Herceptin
The deal includes potential milestone payments of up to $1.9 billion and is expected to close in the second half of 2019.
The company is one of the largest pharmaceutical companies by both market capitalization and sales. In 1996, Ciba-Geigy merged with Sandoz; the pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity.
Read Also: Novartis mulling $1.5 million-$5 million price range for gene therapy Zolgensma
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd